Neuromuscular Fellowship Funding Competition Recipients
The Neuromuscular Disease Network for Canada (NMD4C) together with Muscular Dystrophy Canada (MDC) are excited to announce the recipients of a funding competition, which awarded national post-doctoral fellowships in neuromuscular research and clinical fellowships in neuromuscular medicine and electromyography.
This competition saw many incredible applicants and involved a thorough and extensive review by leading Canadian neuromuscular researchers and clinicians to ensure the most promising and top-ranked researchers, and leaders in neuromuscular care, received funding.
Post-doctoral fellowship recipients:
Dr. Yuguo Liu
Université de Sherbrooke
Post-doctoral Supervisor: Dr. Florian Bentzinger
Title of Research: Targeting the Perivascular MuSC Niche for the Treatment of Muscular Dystrophy
Sean Ng, Ph.C.
McMaster University
Post-doctoral Supervisors: Dr. Mark Tarnopolsky and Dr. Joshua Nederveen
Title of Research: Determining the Therapeutic Potential of AMP-activated Protein Kinase in Myotonic Dystrophy Type 2
Dr. Matthew Triolo
University of Ottawa
Post-doctoral Supervisor: Dr. Mireille Khacho
Title of Research: Targeting mitochondrial dynamics and metabolites to restore muscle stem cell function in Duchenne Muscular Dystrophy
Clinical fellowship recipients:
Dr. Gloria Mak
Training institution: University of Alberta
Dr. Béatrice Soucy
Training institution: University of Calgary
Dr. Neha Patel
Training institution: Sunnybrook Health Sciences Centre, University of Toronto
NMD4C and MDC extend special thanks to the Canadian Society of Clinical Neurophysiologists (CSCN) for jointly funding a clinical fellow this year.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.